SCHEMBL1311222

SCHEMBL1311222

c1ccc2c(c1)oc1c(N3CCOCC3)nc(-c3ccc4cn[nH]c4c3)nc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 12/20 0.60
PIK3CG P48736 3/20 0.60
PIK3CD O00329 2/20 0.60
LMNA P02545 3/20 0.55
MAPK1 P28482 2/20 0.55
TSHR P16473 3/20 0.53
KDM4E B2RXH2 2/20 0.52
MAPT P10636 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SYK P43405 1/20 0.50
BTK Q06187 1/20 0.50
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
PIK3R1 P27986 2/20 0.48
MTOR P42345 2/20 0.48
PIK3C2B O00750 2/20 0.48
PIK3CB P42338 2/20 0.48
PIK3C2A O00443 1/20 0.48
CHUK O15111 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1310077 0.92 LMNA (0.55) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1311619 0.86 PIK3CA (0.68) PIK3CAPIK3CGPIK3CDPIK3R1MTOR
SCHEMBL1309544 0.82 PIK3CA (0.61) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1309869 0.82 PIK3CA (0.58) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1311958 0.81 LMNA (0.60) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1310490 0.80 LMNA (0.53) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1310844 0.80 LMNA (0.54) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1311667 0.79 LMNA (0.64) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL1309730 0.79 LMNA (0.64) PIK3CAPIK3CGPIK3CDLMNAMAPK1
SCHEMBL15374748 0.79 LMNA (0.67) PIK3CAPIK3CGPIK3CDLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD PIK3CA 2/4885PIK3CG 16/4885PIK3CD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.